The Increment of Bone Density in Patients with Spinal Cord Injury after Alendronate Therapy. |
Seo, Jeong Hwan , Lee, Roo Ji , Ko, Myoung Hwan , Park, Sung Hee |
Department of Rehabilitation Medicine, Institute for Medical Science, Chonbuk National University Medical School, Korea. rooji@freechal.com |
척수손상환자에서 Alendronate 복용 후 골밀도의 증가 |
서정환, 이루지, 고명환, 박성희 |
전북대학교 의과대학 재활의학교실, 임상의학연구소 |
|
|
|
Abstract |
Objective The aim of this study was to investigate the changes of bone mineral density (BMD) according to the postinjury duration, walking ability, and to assess the effect of oral alendronate therapy on BMD and biochemical markers in patients with spinal cord injury. Method Forty-eight subjects with spinal cord injury were enrolled. One tablet of AlendⰒ (10 mg of sodium alendronate) was administered daily for 6 months. After this, all subjects received placebo for 6 months as the same manner. The baseline quantitative assessments of BMD and biochemical bone markers, serum osteocalcin and C-terminal telopeptide of type I collagen (ICTP), were performed before the administration of drug. The follow up assess-ments were performed at 6 and 12 months after drug and placebo administration. Results The patients treated with oral alendronate showed significantly higher BMD of femur compared with baseline (p<0.05). Also, ICTP showed significant reduction after alendronate therapy. BMD change rate of alendronate therapy was higher in functional ambulation group compared with wheelchair ambulation group. BMD change rate of alendronate therapy was higher than that of placebo administration. Conclusion Alendronate therapy may be useful in prevention of loss of BMD after spinal cord injury. (J Korean Acad Rehab Med 2005; 29: 187-192) |
Key Words:
Alendronate, Spinal cord injury, Bone mineral density, Biochemical bone marker |
|